Australia's most trusted
source of pharma news
Posted 20 June 2022 AM
All new listings considered at the PBAC's May intracycle meeting were recommended, including Roche's yet to be TGA approved eye drug Vabysmo, which is expected to hit blockbuster status.
The PBAC has recommended listing Vabysmo in two indications - neo-vascular (wet) age-related macular degeneration and diabetic macular oedema.
Its decision sets up a battle with the sponsors of current standard-of-care treatments, including Novartis' (Lucentis) and Bayer's (Eylea).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.